LTR Pharma Co-Founds, Takes Up 33% Stake in Omega-3 Products Firm, Shares Rise Above 3%

MT Newswires Live
2025/09/22

LTR Pharma (ASX:LTP) acquired a 33% equity stake in LevOmega, which was co-founded by Levur, Green Blue Health, and the firm, with no upfront capital required, according to a Monday Australian bourse filing.

LevOmega, which is focused on developing nature-identical omega-3 products, entered into a research and development services and licensing agreement with Levur, under which it will license its proprietary advanced biotechnology platform to LevOmega.

LTR's shares jumped over 3% in recent trading on Monday.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10